Nuvilex Release: KonLin Letter Cites Clinical Trials and Future Partnerships as Rationale for its Projection of Strong Future Revenue

SILVER SPRING, Md.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB:NVLX), today discussed additional aspects of the recent Buy recommendation published in The KonLin Letter, pointing to the potential for development and marketing partnerships that could catapult the company’s valuation and revenue.
MORE ON THIS TOPIC